OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Inclusion Criteria
- Key inclusion criteria: - Adult female or male participants. - ER+, HER2- locally advanced or metastatic breast cancer that is not amenable to curative therapy. - Evaluable disease (measurable disease or bone-only disease). - Previously received a CDK4/6 inhibitor in combination with an endocrine therapy in the advanced setting. One additional line of ET as a monotherapy is allowed. Duration of the most recent prior ET must be at least 6 months. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Adequate hematologic, hepatic, and renal functions. - Female participants can be pre-, peri- or postmenopausal. - Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist. Key exclusion criteria: - Symptomatic visceral disease, imminent organ failure, or any other reason that makes the participant ineligible for endocrine monotherapy. - Previously received chemotherapy in the advanced/metastatic setting. - Previously received treatment with elacestrant or an investigational estrogen receptor-directed therapy. - History of allergic reactions to study treatment. - Any contraindications to the selected standard-of-care endocrine therapy in the local prescribing information. - Symptomatic central nervous system metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require immediate treatment. - Clinically significant comorbidities such as significant cardiac or cerebrovascular disease, gastrointestinal disorders that could affect absorption of study treatment.
Additional locations may be listed on ClinicalTrials.gov for NCT06016738.
Locations matching your search criteria
United States
Arizona
Tucson
Colorado
Aurora
Denver
Highlands Ranch
Lone Tree
Georgia
Atlanta
Illinois
Chicago
Maryland
Baltimore
New York
New York
Oregon
Portland
Texas
Dallas
Houston
This is an international, multicenter, randomized, open-label, active-controlled, phase 3
clinical trial. The purpose of this trial is to compare the safety and efficacy of
palazestrant (OP-1250) as a single agent to the standard of care endocrine therapy:
either fulvestrant or an aromatase inhibitor (anastrozole, letrozole, or exemestane).
This trial is seeking adult participants with ER+, HER2- advanced or metastatic breast
cancer whose disease has relapsed or progressed on 1 or 2 prior lines of standard-of-care
endocrine therapy for metastatic breast cancer. Prior lines of therapy must include one
line of endocrine therapy in combination with a CDK 4/6 inhibitor. In the dose-selection
part of the trial, approximately 120 participants will be randomized to one of the two
doses of palazestrant or to the standard-of-care endocrine therapy. Thereafter,
approximately 390 participants will be randomized to palazestrant at the selected dose or
to the standard-of-care endocrine therapy.
Trial PhasePhase III
Trial Typetreatment
Lead OrganizationOlema Pharmaceuticals, Inc.
- Primary IDOP-1250-301
- Secondary IDsNCI-2023-09687, OPERA-01
- ClinicalTrials.gov IDNCT06016738